Raghad

PharmD Graduate💊|@Rx_simplified | Plotting the next move?…🏎️

[Raghad @Ragicllin]

I was born to be anything i want

[Aseel Swaid @aseelswaid9]

Rose harvest in Saudi Arabia

[Raghad @Ragicllin]

لم تكن هذه السنوات شيئًا مررتُ به، بل شيئًا مرّ بي وغيّرني
الحمد لله على ما علّمني إياه هذا المشوار، وعلى كل بابٍ أُغلق ليقود إلى بابٍ أجمل، وعلى كل حلم تحقق، والأحلام التي تنتظر موعدها.
هذه ليست النهاية التي أركض نحوها، بل البداية التي كانت تركض نحوي.

الحمد لله دائمًا وأبدًا🤍

[Raghad @Ragicllin]

@Ninjaappksa باذن الله اطلب كيكة التخرج من عندكم

[Raghad @Ragicllin]

🎓ـــذاكـرة آخـر فاينـل في مسيـرتي الجامعية !

[Raghad @Ragicllin]

Long story short, I SurVvViiiveEeeDd

[Raghad @Ragicllin]

@DrHawazn 😭😭😭😭😭😭😭😭😭😭

[Raghad @Ragicllin]

💌 A little reminder that:
Everything you lose is a step you take.

[Raghad @Ragicllin]

@sscpCCEmpsn Balanced crystalloids (e.g., Lactated Ringer’s or Plasma-Lyte). SSC recommends crystalloids as first-line fluids and suggests balanced crystalloids over normal saline for initial resuscitation in septic shock.

[Raghad @Ragicllin]

But patients aren’t equations and medicine isn’t always black and white.Sometimes the hardest part isn’t finding the answer, it’s deciding which answer to trust.

That’s what makes medicine challenging and humbling 💯

[Raghad @Ragicllin]

I sometimes wish clinical practice were as simple as math.

In math, 1 + 1 always equals 2

In clinical practice, the same evidence can lead to different decisions, and the right answer often depends on the patient sitting in front of you

[Josh Farkas MD 💊 @PulmCrit]

REMAP-CAP Oseltamavir arm:

Let me preface this by saying that I've never been a big oseltamivir fan (seriously, who is?).

I'd love to see oseltamivir proven ineffective so I'd never need to argue about it ever again.

But I don't think the math here works.

Applying a Fisher's exact score to the mortality difference yields a p-value of 0.17 which is nowhere *close* to statistically significant (by any standard).

I'm increasingly tired of seeing these studies where the p-value is ginormous but the study claims to be a slam-dunk (98% risk of harm!).

Stopping a trial prematurely for harm with a p-value of 0.17 will ultimately lead to a lot of confusion about what this study means (spoiler alert: probably not much).

Hopefully the manuscript will clarify this, but the math doesn't seem to be mathing. If you're going to claim 98% certainty of a result, then the results should be consistent regardless of how you run the statistics.

Just to be clear, I despise oseltamivir, but I'm worried that we're going down a slippery slope when a Bayesian wonderland somehow converts p=0.17 into 98% certainty.

[Raghad @Ragicllin]

@NouraFlout So nice of you💞 Likewise!

[Raghad @Ragicllin]

#studytwt

[Raghad @Ragicllin]

To. Live. For. The. Hope. Of. It. All.

[Raghad @Ragicllin]

@BageLeMage @NEJM @NEJMClinician Good point. AI-augmented real-world evidence could definitely provide additional insights

[Raghad @Ragicllin]

Congratulations to all shortlisted pharmacy residency candidates!🌟

Wishing you smooth interviews, great opportunities, and a well-deserved matching🎊

#matching2026 #matching_2026

[Raghad @Ragicllin]

I’ve lived long enough to know that not everything needs to make sense right away.
Some things reveal their meaning only after the pieces come together.

[Raghad @Ragicllin]

@Ph_marwa95 Congratulations 🌟 well deserved

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO